Abbvie Inc. · NYSE:ABBV

Abbvie — Q4 2022 Earnings Presentation

4 slides from Abbvie's earnings presentation, Feb 9, 2023

  1. Slide 1: AbbVie Pipeline Update

    AbbVie Pipeline Update February 9, 2023

  2. Slide 2: AbbVie R&D Pipeline

    AbbVie R&D Pipeline Phase 1 Phase 2 Registrational / Phase 3 Submitted ■ CUG-252* (IL-2 Mutein) SLE ■ ABBV-154 (TNF-Steroid ADC) PMR ■ Rinvoq (JAK 1) GCA ■ Rinvoq (JAK 1) CD ■ CLF065* (GLP-2 agonist) IBD ■ ABBV-154 (TNF-Steroid ADC) CD ■ Skyrizi* (IL-23) UC ■ Epcoritamab* (CD3-CD20): R/R DLBCL ■ ABB

  3. Slide 3: AbbVie - Anticipated Key Pipeline Events

    AbbVie - Anticipated Key Pipeline Events 2023 2024 Regulatory Rinvoq CD Skyrizi UC Teliso V 2L+ NSCLC (AA) Epcoritamab R/R DLBCL (AA) Venclexta 3L+ MM w/ t(11;14) Botox Platysma Approvals ABBV-951 Advanced PD Venclexta High Risk MDS Botox Masseter Qulipta Chronic Migraine Prevention Navitoclax 1L MF

  4. Slide 4: AbbVie's Partnered Assets

    AbbVie’s Partnered Assets • ABBV-2029 developed by CytomX Therapeutics through clinical proof of concept and AbbVie holds option for additional development • ABBV-647 developed in cooperation with Pfizer • ABBV-CLS-579/484/7262 co-developed by Calico and AbbVie • Acazicolcept (ALPN-101) developed by

AbbVie — Q4 2022 Earnings Presentation on 6ix